Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 2
2019 1
2020 5
2021 11
2022 14
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Onoi K, et al. Among authors: morimoto y. J Clin Med. 2020 May 6;9(5):1362. doi: 10.3390/jcm9051362. J Clin Med. 2020. PMID: 32384677 Free PMC article. Review.
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.
Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, Takayama K. Tanimura K, et al. Among authors: morimoto y. NPJ Precis Oncol. 2022 Jan 18;6(1):5. doi: 10.1038/s41698-021-00250-8. NPJ Precis Oncol. 2022. PMID: 35042943 Free PMC article.
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Katayama Y, et al. Among authors: morimoto y. Cancer Med. 2022 Feb;11(4):944-955. doi: 10.1002/cam4.4504. Epub 2022 Jan 14. Cancer Med. 2022. PMID: 35029047 Free PMC article.
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Nakamura R, et al. Among authors: morimoto y. J Cancer Res Clin Oncol. 2022 Nov;148(11):2985-2994. doi: 10.1007/s00432-021-03866-2. Epub 2021 Nov 26. J Cancer Res Clin Oncol. 2022. PMID: 34825950
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC.
Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: morimoto y. JTO Clin Res Rep. 2022 Aug 6;3(9):100388. doi: 10.1016/j.jtocrr.2022.100388. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082280 Free PMC article.
Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.
Uda S, Yamada T, Yoshimura A, Goto Y, Yoshimine K, Nakamura Y, Shiotsu S, Yokoi T, Tamiya N, Kimura H, Chihara Y, Umeda Y, Izumi M, Takeda T, Yamada T, Hibino M, Hiranuma O, Ito K, Okada A, Osugi S, Takemura Y, Ishii H, Chibana K, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Uda S, et al. Among authors: morimoto y. Transl Lung Cancer Res. 2022 Sep;11(9):1847-1857. doi: 10.21037/tlcr-22-160. Transl Lung Cancer Res. 2022. PMID: 36248326 Free PMC article.
33 results